![Patrick Paul Mc Ilvenny](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrick Paul Mc Ilvenny
Chief Executive Officer at Horizon Therapeutics Switzerland GmbH
Network origin in Patrick Paul Mc Ilvenny first degree
Entity | Entity type | Industry | |
---|---|---|---|
Horizon Therapeutics Switzerland GmbH
![]() Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Patrick Paul Mc Ilvenny via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
UBS Securities LLC
![]() UBS Securities LLC Investment ManagersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Managers | Director/Board Member | |
AFFIMED N.V. | Biotechnology | Director of Finance/CFO | |
The Trustees of Columbia University in The City of New York | College/University | Masters Business Admin | |
EUROPEAN MEDICAL SOLUTIONS | Biotechnology | Director/Board Member | |
BiognoSYS AG
![]() BiognoSYS AG Packaged SoftwareTechnology Services BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland. | Packaged Software | Chairman | |
Novaremed AG
![]() Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Pharmaceuticals: Major | Chairman | |
ProteoMediX AG
![]() ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | Biotechnology | Chairman | |
BioSupport AG | Director/Board Member | ||
Anokion SA
![]() Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member | |
Kanyos Bio, Inc.
![]() Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Fondation De l'Hôpital Barrie Memorial
![]() Fondation De l'Hôpital Barrie Memorial Miscellaneous Commercial ServicesCommercial Services Fondation De l'Hôpital Barrie Memorial is a private company based in Ormstown, Canada. The Canadian company engages in raising funds to improve health care and services. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
KUROS BIOSCIENCES AG | Biotechnology | Director of Finance/CFO | |
HBM Fondation | Corporate Officer/Principal | ||
Virometix AG
![]() Virometix AG Pharmaceuticals: MajorHealth Technology Virometix AG is a Swiss biotechnology company that focuses on developing vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. Virometix is based in Schlieren, CH. The private company's mission is to address the growing medical need for vaccines to combat infectious and chronic human diseases. The company was founded by John Anthony Robinson, and the CEO is Anna Sumeray. | Pharmaceuticals: Major | Chairman | |
Kuros Biosciences AG
![]() Kuros Biosciences AG Miscellaneous Commercial ServicesCommercial Services Kuros Biosciences AG is a Swiss company that specializes in developing innovative solutions for targeted and controlled bone healing. The private company is based in Schlieren, Switzerland. The company's mission is to eliminate non-unions and improve patient rehabilitation. | Miscellaneous Commercial Services | Director/Board Member | |
Affimed GmbH
![]() Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
Switzerland | 14 |
United States | 5 |
Germany | 3 |
Belgium | 2 |
Canada | 2 |
Sectoral
Health Technology | 11 |
Commercial Services | 6 |
Finance | 2 |
Consumer Services | 2 |
Technology Services | 2 |
Operational
Director/Board Member | 15 |
Director of Finance/CFO | 5 |
Chairman | 4 |
Corporate Officer/Principal | 4 |
Independent Dir/Board Member | 2 |
Most connected contacts
Insiders | |
---|---|
Harry Welten | 22 |
- Stock Market
- Insiders
- Patrick Paul Mc Ilvenny
- Company connections